Erratum: Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells (International Journal of Cancer (2012) 130 (2259-2270) DOI: 10.1002/ijc.26228);Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2259-2270

  Messina, Rosa Linda ^a   Sanfilippo, Mariangela ^a   Vella, Veronica ^a   Pandini, Giuseppe ^a   Vigneri, Paolo ^a   Nicolosi, Maria Luisa ^a   Gianì, Fiorenza ^a   Vigneri, Riccardo ^a   Frasca, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

apoptosis; cell proliferation; p53 mutant; p73; Prima 1; thyroid cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MESSENGER RNA; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS; PACLITAXEL; PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BAX GENE; CANCER CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MDM2 GENE; MUTANT; P21 WAF1 GENE; PRIORITY JOURNAL; THYROID CANCER; UPREGULATION; WILD TYPE;

EID: 84859103002     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27697     Document Type: Erratum

References (49)

1. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK,. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93: 824-42. (Pubitemid 32586611)
2. Gomez Segovia I, Gallowitsch HJ, Kresnik E, Kumnig G, Igerc I, Matschnig S, Stronegger WJ, Lind P,. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984-2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid 2004; 14: 277-86. (Pubitemid 38569277)
3. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M,. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 2007; 17: 639-46. (Pubitemid 47311553)
4. Xing M,. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62. (Pubitemid 350294294)
5. Xing M,. Gene methylation in thyroid tumorigenesis. Endocrinology 2007; 148: 948-53.
6. Farid NR,. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 2001; 24: 536-45. (Pubitemid 32691169)
7. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP,. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91: 179-84. (Pubitemid 23037270)
8. Munro AJ, Lain S, Lane DP,. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-44. (Pubitemid 40395523)
9. Wang W, El-Deiry WS,. Targeting p53 by PTD-mediated transduction. Trends Biotechnol 2004; 22: 431-4. (Pubitemid 39141152)
10. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T,. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 1998; 83: 2516-22. (Pubitemid 28503056)
11. Imanishi R, Ohtsuru A, Iwamatsu M, Iioka T, Namba H, Seto S, Yano K, Yamashita S,. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab 2002; 87: 4821-4. (Pubitemid 35247082)
12. Hassan I, Wunderlich A, Burchert A, Hoffmann S, Zielke A,. Antisense p53 oligonucleotides inhibit proliferation and induce chemosensitivity in follicular thyroid cancer cells. Anticancer Res 2006; 26: 1171-6.
13. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G,. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-8. (Pubitemid 34250107)
14. Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M,. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008; 15: 718-29. (Pubitemid 351405077)
15. Wiman KG,. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006; 13: 921-6.
16. Moon C, Oh Y, Roth JA,. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9: 5055-67. (Pubitemid 37413553)
17. Douglas JT,. Adenoviral vectors for gene therapy. Mol Biotechnol 2007; 36: 71-80. (Pubitemid 350133603)
18. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA,. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8. (Pubitemid 38174664)
19. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933-8. (Pubitemid 351723502)
20. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR,. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002; 21: 2119-29. (Pubitemid 34311366)
21. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M,. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004; 127: 285-91. (Pubitemid 39468941)
22. Magrini R, Russo D, Ottaggio L, Fronza G, Inga A, Menichini P,. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J Cell Biochem 2008; 104: 2363-73.
23. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS,. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 2005; 7: R765-74.
24. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ,. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-88.
25. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ,. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010; 29: 1329-38.
26. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T,. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-73. (Pubitemid 40544653)
27. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr., Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-10. (Pubitemid 38340308)
28. Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R, Vigneri P,. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003; 63: 5829-37. (Pubitemid 37187481)
29. Strano S, Blandino G,. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle 2003; 2: 348-9.
30. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K, Harris CC,. Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 1999; 18: 3415-21. (Pubitemid 29286988)
31. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT,. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010; 29: 6442-51.
32. Wang W, Kim SH, El-Deiry WS,. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103: 11003-8. (Pubitemid 44148408)
33. Bykov VJ, Issaeva N, Selivanova G, Wiman KG,. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23: 2011-8. (Pubitemid 36104953)
34. Stiewe T, Putzer BM,. p73 in apoptosis. Apoptosis 2001; 6: 447-52. (Pubitemid 33078755)
35. Moretti F, Nanni S, Farsetti A, Narducci M, Crescenzi M, Giuliacci S, Sacchi A, Pontecorvi A,. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 2000; 85: 302-8. (Pubitemid 32268830)
36. Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzo M, Bonfil RD, Fabra A,. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 1999; 6: 22-33. (Pubitemid 29043690)
37. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, Blandino G,. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275: 29503-12. (Pubitemid 32043826)
38. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Jr, Magrath I, Kohn KW, O'Connor PM,. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-30.
39. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K,. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996; 122: 360-5. (Pubitemid 26168545)
40. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M,. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 870-4. (Pubitemid 27098011)
41. Malaguarnera R, Vella V, Vigneri R, Frasca F,. p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007; 14: 43-60. (Pubitemid 47521721)
42. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G,. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817-26. (Pubitemid 34952441)
43. Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, Frasca F,. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. Mol Cancer Res 2008; 6: 64-77. (Pubitemid 351378167)
44. Bourdon JC,. p53 Family isoforms. Curr Pharm Biotechnol 2007; 8: 332-6.
45. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG,. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 2001; 11: 315-25. (Pubitemid 32422623)
46. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH,. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002; 132: 984-90; discussion 90. (Pubitemid 36026945)
47. Puppin C, Passon N, Frasca F, Vigneri R, Tomay F, Tomaciello S, Damante G,. In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. Cell Oncol (Dordr) 2011; 34: 131-40.
48. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG,. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24: 3484-91. (Pubitemid 40756249)
49. Liang Y, Besch-Williford C, Benakanakere I, Hyder SM,. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Int J Oncol 2007; 31: 777-84.